Latest News

Quanta News

John S. Lipman Appointed as Quanta’s President, North America.

24th November 2020

Alcester, Warwickshire, UK.  24 November 2020.  Seroba’s portfolio company, Quanta Dialysis Technologies Ltd (“Quanta” or the “Company”), a medical technology company developing innovative dialysis products and services, has announced the appointment of John S. Lipman as Quanta’s  President, North America. […]

Read More
Home V2

Storm Therapeutics and Evotec Leverage Indigo Platform to Progress Oncology Project.

17th November 2020

Storm’s First-in-Class clinical candidate against an RNA Methyltransferase for use in Cancer was identifed with support from Evotec’s Drug Discovery Engine. Storm will progress the compound towards the clinic using indigo, Evotec’s integrated Ivestigational New Drug (IND) enabling Platform. Hamburg, […]

Read More
Pq Bypass

PQ Bypass Releases Positive 24-Month Data from the DETOUR1 Clinical Trial.

13th November 2020

MILPITAS, Calif.  November 12, 2020.  Seroba’s portfolio company, PQ Bypass, Inc, a medical device pioneer bringing new advancements to the treatment of complex peripheral artery disease (PAD), announced promising long-term safety and effectiveness results from 24-month follow-up data from the […]

Read More
Heidi Zac Image

Heidi Zak, CEO of ThirdLove, joins INNOVO® in advisory role.

10th November 2020

BOSTON, Nov. 10, 2020 Seroba’s portfolio company, Atlantic Therapeutics, has announced that Heidi Zak, co-founder and CEO of ThirdLove will take on an advisory role in the acceleration of the INNOVO® brand. INNOVO® is a direct-to-consumer, FDA-approved medical device offering […]

Read More
Da73c103 A854 419d 8527 Ed1475347af1

Fusion Pharmaceuticals Announces Collaboration With AstraZeneca To Develop And Commercialize Next-Generation Radiopharmaceuticals And Combination Therapies.

2nd November 2020

Hamilton, Ontario and Boston, 2 November 2020.  Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced a collaboration with AstraZeneca (LSE/STO/Nasdaq: AZN) to develop and commercialize next-generation alpha-emitting radiopharmaceuticals and […]

Read More
STORM Therapeutics Logo

STORM Therapeutics selects first-in-class clinical candidate targeting METTL3

22nd October 2020

22 October 2020, Cambridge, UK: Seroba’s investee company, STORM Therapeutics, the leading biotechnology company focused on the discovery and development of small molecule therapies modulating RNA epigenetics, has announced  that STC-15, its first-in-class drug candidate targeting METTL3, has been selected […]

Read More
T: 353 (0)1 633 4028

18 Herbert Street
Dublin 2
D02 FK19
Ireland

Scroll to Top